Heather Collier
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 6
-
- Epilepsy research and treatment 3
- Journals
- The Lancet (6 papers)Nature (2 papers)Brain Communications (2 papers)JAMA (1 paper)npj Genomic Medicine (1 paper)
- Partner nations
- United KingdomVietnamNetherlands
In The Last Decade
Heather Collier
12 papers receiving 1.8k citations
Heather Collier's Hit Papers
Peers
Comparison fields: 5 of 87
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 28
- Statistics and Probability 50
- Pulmonary and Respiratory Medicine 111
Countries citing papers authored by Heather Collier
This map shows the geographic impact of Heather Collier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Collier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Collier more than expected).
Fields of papers citing papers by Heather Collier
This network shows the impact of papers produced by Heather Collier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Collier. The network helps show where Heather Collier may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 8 | 2023 | 60 | |
| 9 | 2022 | 55 | |
| 10 | 2023 | 9 | |
| 11 | 2022 | 6 | |
| 12 | 2023 | 6 | |
| 13 | 2022 | 0 |
About Heather Collier
Heather Collier is a scholar working on Infectious Diseases, Psychiatry and Mental health, Genetics, Economics and Econometrics and Pulmonary and Respiratory Medicine, having authored 13 papers that have together received 1.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), Epilepsy research and treatment (3 papers), Genetic Associations and Epidemiology (2 papers), Respiratory Support and Mechanisms (1 paper) and Health Systems, Economic Evaluations, Quality of Life (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (28 citations), Statistics and Probability (50 citations) and Pulmonary and Respiratory Medicine (111 citations). Heather Collier has collaborated with scholars based in United Kingdom, Vietnam and Netherlands. Their work appears in journals such as The Lancet, Nature, Brain Communications, JAMA and npj Genomic Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.